Allogene Therapeutics (NASDAQ:ALLO) SVP Annie Yoshiyama Sells 9,586 Shares of Stock

Allogene Therapeutics, Inc. (NASDAQ:ALLO) SVP Annie Yoshiyama sold 9,586 shares of the stock in a transaction dated Tuesday, April 21st. The stock was sold at an average price of $2.31, for a total transaction of $22,143.66. Following the transaction, the senior vice president directly owned 124,517 shares in the company, valued at $287,634.27. This trade represents a 7.15% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Annie Yoshiyama also recently made the following trade(s):

• On Monday, February 2nd, Annie Yoshiyama sold 4,167 shares of Allogene Therapeutics stock. The stock was sold at an average price of $1.72, for a total value of $7,167.24.

Allogene Therapeutics Stock Performance

Shares of NASDAQ:ALLO opened at $2.35 on Friday. Allogene Therapeutics, Inc. has a 52-week low of $0.86 and a 52-week high of $4.46. The business’s 50 day simple moving average is $2.40 and its two-hundred day simple moving average is $1.76. The firm has a market cap of $575.33 million, a P/E ratio of -2.70 and a beta of 0.53.

Allogene Therapeutics (NASDAQ:ALLO) last released its quarterly earnings data on Thursday, March 12th. The company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.08. On average, equities analysts forecast that Allogene Therapeutics, Inc. will post -0.73 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Allogene Therapeutics

Hedge funds have recently bought and sold shares of the company. Kestra Private Wealth Services LLC purchased a new stake in shares of Allogene Therapeutics in the first quarter valued at about $27,000. Krilogy Financial LLC purchased a new position in Allogene Therapeutics during the first quarter worth about $40,000. Savant Capital LLC bought a new stake in Allogene Therapeutics in the 3rd quarter worth about $27,000. Russell Investments Group Ltd. grew its position in Allogene Therapeutics by 11,159.8% in the 3rd quarter. Russell Investments Group Ltd. now owns 21,844 shares of the company’s stock worth $27,000 after purchasing an additional 21,650 shares in the last quarter. Finally, Mercer Global Advisors Inc. ADV purchased a new stake in Allogene Therapeutics in the 3rd quarter valued at about $30,000. 83.63% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

ALLO has been the topic of several research reports. Canaccord Genuity Group restated a “buy” rating and set a $14.00 price objective on shares of Allogene Therapeutics in a report on Friday, March 13th. Jefferies Financial Group boosted their target price on shares of Allogene Therapeutics from $6.00 to $10.00 and gave the stock a “buy” rating in a research report on Monday, April 13th. Citigroup restated an “outperform” rating on shares of Allogene Therapeutics in a report on Tuesday, April 14th. Wall Street Zen raised shares of Allogene Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, February 22nd. Finally, HC Wainwright boosted their price objective on Allogene Therapeutics from $8.00 to $12.00 and gave the stock a “buy” rating in a report on Tuesday, April 14th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $8.44.

Allogene Therapeutics Company Profile

Allogene Therapeutics is a clinical-stage biotechnology company focused on developing allogeneic, or “off-the-shelf,” chimeric antigen receptor T-cell (CAR T) therapies to treat a range of hematologic malignancies and solid tumors. The company leverages gene-editing technologies to generate universally compatible engineered T cells, aiming to overcome the limitations of patient-specific CAR T approaches such as manufacturing delays, variable product quality and treatment resistance.

The company’s pipeline includes multiple allogeneic CAR T candidates targeting key antigens in blood cancers.